ניוזלטר של האגודה הישראלית לאנדוקרינולוגיה | נובמבר 2014

כנסי האגודה

כנס חורף IES 2014 יתקיים השנה במלון הנסיכה באילת ב 27-29/11/14
ההרשמה בעיצומה. תוכנית מדעית וטפסים להרשמה באתר האגודה. לינק >>>

הכנס השנתי IES 2015 יתקיים הפעם באשקלון ב 14-15/4/15
פרופ’ יוסי אורלי נבחר ליו”ר הכנס וחברי האיגוד מוזמנים לפנות אליו עם רעיונות והצעות
למושבים ומרצים. פרטים נוספים יעודכנו בלינק הבא

קול קורא למלגות מחקר של האגודה

חברי האגודה מוזמנים להגיש בקשות לשתי מלגות מחקר במימון האגודה המיועדים לחוקרים צעירים
בתחומים קליניים או בסיסים בסך 40,000 ₪ כ”א. הוראות וקריטריונים פורסמו באתר

European Council of Affiliated Societies

המפגש השלישי של ECAS התקיים בסוף אוקטובר עם נוכחות של 31 מתוך 38 איגודים מקומיים.
ד”ר Mastorakos מהאיגוד היווני נבחר כנציג ECAS לוועד המרכזי של ESE. נציגי האיגודים המקומיים הציגו את כרטיסי הביקור של כל איגוד, ד”ר בן בסט ייצג את IES. ב-ESE חברים כ-3,000 איש. למרות מספר קטן של חברי IES בתוך ESE (כ-5 אחוז מכלל חברי IES) המצב לא שונה בהרבה מיתר האיגודים. האיגודים עם הנוכחות הגבוהה ביותר ב-ESE (גם אבסולוטי וגם באחוזים) הם פולין, אנגליה ואיטליה. בראש האג’נדה של ECAS נמצא נושא ה-syllabus, כאשר הכוונה ליצור התמחות דומה בין כל המדינות כפלטפורמה לאפשרות עתידית של אקרדיטציה אחידה. נושאים נוספים הם: העלאת מספר חברים ב ESE, סיוע ל -ESE בפיתוח תוכניות מדעיות ועוד. הבחירות לנשיא ESE חדש מתקרבות ויתבצעו בצמוד לכנס השנתי במאי 2015 ב- Dublin. זו ההזדמנות להזמין את חברי IES להירשם ל ESE, להשפיע וליהנות ממחיר חבר בהרשמה לכנס. לינק >>>

European Society of Endocrinology

לצפייה בניוזלטר סתיו וחדשות חודש אוקטובר של ESE לחצו כאן

ההסתדרות הרפואית בישראל

למידעון הר”י לחודש נובמבר  לינק>>>

איגודים אנדוקרינים בעולם

בספטמבר 2014 התקיים הכנס ה-31 של Brazil Society of Endocrinology and Metabolism
בכנס, שנערך בשיתוף פעולה עם ESE, הייתה נוכחות מרשימה של 4,200 משתתפים. האגודה האנדוקרינית בברזיל היא השלישית בגודלה בעולם.

• ב 21/11/14 – ENS@T Scientific Meeting (Nice)
• ב 27/11/14 – כנס חורף של אגודה ישראלית לאנדוקרינולוגיה (אילת)
• ב 05/03/15 – ENDO 2015 Meeting (San Diego)
• ב 26/03/15 – World Congress on Osteoporosis (Milan)
• ב 11/03/14 – ENETS Annual Conference (Barcelona)
• ב 14/04/15 – הכנס השנתי IES 2015 של האגודה הישראלית לאנדוקרינולוגיה (אשקלון)
• ב 16/05/15 – European Congress of Endocrinology (Dublin)

American Society of Clinical Oncology Position Statement on Obesity and Cancer
להמשך קריאה

ADA, AACE, EASD and Endocrine society in response to The Lancet
Standing up with a united strong voice for ethical publishing in science and medicine devoid of divisive politicization. Today we salute the executives of the American Association of Clinical Endocrinology, the American Diabetes Association, the Endocrine Society, and the European Association for the Study of Diabetes, as well as their Journal Editors, for their unambiguous call to dissociate the publishing of medicine and science from the contentious political issues that put obstacles in our way and make it more difficult to achieve our core goals of improving healthcare all over the world. Please see all of their Journal Websites for this joint communication. Daniel Drucker
להמשך קריאה

FDA Approves Two-In-One Diabetes Treatment.
Reuters reports that AstraZeneca has won US FDA approval for its Xigduo XR, a new two-in-one diabetes pill that combines the newer dapagliflozin with an older metformin.
להמשך קריאה

Lilly, BI Alter Terms Of Diabetes Drug Partnership.
Eli Lilly and Boehringer Ingelheim announced they altered terms of their alliance to develop and market diabetes drugs, originally signed in 2011 applying to 50 countries. The two pharmas would keep jointly producing and selling treatments in 17 nations, 90 percent of the drugs market. In other countries, each pharma will sell in separate.  In the three years since its inception, the alliance introduced three diabetes drugs – Trajenta, Jardiance and Jentadueto – and a new insulin glargine that received tentative approval.
להמשך קריאה

Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes 
The results from post-trial follow-up ADVANCE Study designed to test the hypotheses that there would be long-term benefits of two active interventions have been reported. The benefits with respect to mortality observed among patients originally assigned to blood-pressure-lowering therapy were attenuated but still evident at the end of follow-up, but there was no evidence that intensive glucose control during the trial led to long-term benefits with respect to mortality or macrovascular events.
להמשך קריאה

Fail To Identify Young Postmenopausal Women At Risk For OP Fractures.
A paper in JCEM analyzed data from more than 62,000 postmenopausal women in the United States, ages 50 to 64, and found that the US Preventive Services Task Forces recommendations identified only about 26 percent of women who suffered major osteoporosis-related fractures within 10 years. The research indicated that two older osteoporosis risk assessment tools – the Simple Calculated Osteoporosis Risk Estimation Tool (SCORE) and the Osteoporosis Self-Assessment Tool (OST) – were not much better, identifying about 39 percent and 40 percent of women at risk, respectively.
להמשך קריאה

Kids Who Do Not Drink Cow’s Milk May Have Insufficient Levels Of Vitamin D.
Research in CMAJ suggests that kids who do not drink cow’s milk may have insufficient vitamin D LEVELS. Researchers tracked D levels in 2,831 children under age of 6. Ten  percent did not drink milk from cows and were three times more likely to have D levels below 20 ng/ml.
להמשך קריאה

Phthalates In Women Can Lead To Low Libido.
Research presented at the American Society for Reproductive Medicine found that women with the highest concentrations of “phthalates” in their bodies – chemicals used to make plastics bendy – were far more likely to suffer low libido
להמשך קריאה

FDA Approves Remote Glucose-Monitoring Tool.
The FDA approved Dexcom device to remotely monitor glucose at regular intervals sending data to a receiver within 20 feet of the patient. The cradle allows data to be sent to apps on smartphones. However, it has to be plugged into electrical outlet so it won’t be useful when the patient is outside. Yet, it is a first step towards true remote monitoring.
להמשך קריאה

Company Says Oral Insulin Performed Well In Study.
Israel-based biotechnology firm Oramed Pharmaceuticals disclosed its ORMD-0801 oral insulin capsule performed well in a phase 2 trial. The oral medicine was being tested in 25 participants suffering from type 1 diabetes
להמשך קריאה

Emil Theodor Kocher (1841-1917) was a Swiss physician who received the 1909 Nobel Prize in Physiology or Medicine for his work in the physiology, pathology and surgery of the thyroid. He was the first surgeon to ever receive a Nobel prize. He started his studies in 1858 at the University of Bern and obtained his doctorate summa cum laude under professor Biermer. In 1865, Kocher followed Biermer to Zurich, where Theodor Billroth was director of the hospital and influenced Kocher significantly. Two years later returned to Bern and wrote a petition to award him the venia docendi (Latin: to instruct) which got granted. He married in 1869 and had three children. He became assistant to Georg Lücke who left Bern in 1872. Kocher was hoping to get his position, but the faculty suggested Franz König. The students, assistants and many doctors preferring Kocher petitioned the Bernese government to choose Kocher. Also famous foreign surgeons, such as Langenbeck from Berlin and Billroth from Vienna, wrote letters in support of Kocher. Finally, the Bernese government elected him as the next Ordinary Professor of Surgery and Director of the University Surgical Clinic at the Inselspital. The call for an ordinary professorship at the University of Bern at the age of 30 was his first big career step. In the 45 years he served as professor at the university, he oversaw the re-building of the Bernese Inselspital, published 249 scholarly articles and books, trained numerous medical doctors and treated thousands of patients. His major contributions were in the fields of applied surgery, neurosurgery and, especially, thyroid surgery and endocrinology. Thyroid surgery, as treatment of goitre with a complete thyroidectomy, was considered a risky procedure when Kocher started his work having an estimated mortality as high as 75% in 1872. It was believed to be one of the most dangerous operations. Through modern surgical methods, such as antiseptic wound treatment and minimizing blood loss, and the famous slow and precise style of Kocher, he managed to reduce the mortality to less than 0.5% by 1912. By then, Kocher had performed over 5000 thyroid excisions. Kocher and others later discovered that the complete removal of the thyroid could lead to cretinism (termed cachexia strumipriva by Kocher). The phenomenon was reported to Kocher first in 1874 by general practitioner August Fetscherin and later in 1882 by Jacques-Louis Reverdin. Kocher then tried to contact his former patients and found physical and mental decay in those where he had removed the thyroid completely. Kocher came to the conclusion that a complete removal of the thyroid was not advisable, a finding that he made public in about thyroidectomies and their consequences. Reverdin had already made his findings public on September 1882 and published further articles in 1883; yet still Kocher never acknowledged Reverdin’s priority in this discovery. Kocher became rector of the university in 1878 and president of the Bernese and the Swiss physicians association in 1903, president of the Bernese and the Swiss physicians association and co-founded the Swiss society for surgery in 1913. He catered to the wealthier patients, which in many cases were international like Lenin’s wife, Nadezhda Krupskaya on whom he operated in 1913. On the evening of 23 July 1917, he was called into the Inselspital for an emergency. Kocher executed the surgery but afterwards felt unwell and went to bed, fell unconscious and died on 27 July 1917. (Source: Wikipedia)